Expanding Portfolio
Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis
Colin Kerr
Published: Friday, February 1, 2019
Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis.
The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials.
Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.”
www.oculis.com
Tags: anti-TNF alpha antibody, ophthalmic disease
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.